Role of MRI in Diagnosis of Pulmonary Embolism

May 24, 2020 updated by: HMMostafa, Assiut University
The aim of this work is to emphasize the role of non-contrast MR imaging in diagnosis of acute pulmonary embolism in comparison to CTA and contrast enhanced MRA as gold standard techniques.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Pulmonary embolism (PE) is a serious condition responsible for significant morbidity and mortality. PE is currently the third leading cause of cardiovascular death worldwide, so it requires prompt diagnosis and treatment to prevent potentially deadly consequences (1) . Pulmonary embolism occurs when a blood clot-usually from the leg-travels to the lung and blocks the pulmonary artery or one of its branches (2). The diagnosis of acute PE is considered a clinical dilemma due to wide spectrum of multiple nonspecific signs and symptoms (3) .

The D-dimer results are of bad positive laboratory test being positive in other situations rather than PE such as cancer and inflammation (4) .

CT pulmonary angiography (CTA) is highly sensitive and specific for the diagnosis of PE and has become the imaging method of choice in patients suspected of having PE. The multislice CT offered high spatial and temporal resolution imaging in a short time scan. CTA has the ability to assess the pulmonary tree down to the fifth and to eighth order branches in less than 15 seconds due to high speed (5).

However, Limitations of CTPA include exposure to ionizing radiation with its risk of cancer induction and iodinated contrast agent, which carries a risk of allergic reactions and kidney damage and failure in some patients (6) .Many patients with suspected PE, such as pregnant women and patients with impaired renal function, have at least a relative contraindication to contrast media irradiation.

MRI offers a potential alternative to CTPA in the evaluation of the pulmonary vasculature and the diagnosis of PE [7]. To date, however, the majority of studies evaluating the use of MRI in the diagnosis of PE have used gadolinium based intravenous contrast media, which is contraindicated in pregnant patients and in those with renal failure [8].

So, alternatively non contrast MRA improves diagnostic accuracy and simplify the acquisition techniques remains an area of clinically important development. The non-contrast MRA produces enhancing signal from the vessel wall, provides high contrast with no need for bolus timing and provides motion-insensitivity to respiration (9).

The purpose of this study to evaluate the feasibility of detecting pulmonary emboli using non contrast bright blood and dark blood MR imaging techniques.

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Assiut, Egypt, 020
        • Hossam Mohammed Mostafa

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

  1. Full history taking and clinical examination.
  2. CT PA or contrast enhanced MR PA.

Description

Inclusion Criteria:

  • High clinical probability of PE assessed by the revised Geneva score and / or had a D- dimer level > 500 µg L1 on an ELISA-based test
  • Patients with clinically evident and confirmed by CT PA or contrast enhanced MR-PA to have PE .
  • Both sexes will be included in addition to pregnant women.
  • No age predilection but children Less than 18 years old will not be included

Exclusion Criteria:

  • Patients known to have contraindication for MRI, e.g. an implanted magnetizable device, metallic ocular implant, pacemakers, or claustrophobia.
  • Patients with bad general condition with signs of a severe PE such as unstable haemodynamic.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
detection of pulmonary embolism by MRI without contrast administration
Time Frame: baseline
diagnosis and detection of pulmonary embolism by MRI in comparison with MSCT pulmonary angiography
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2018

Primary Completion (Actual)

January 1, 2020

Study Completion (Actual)

April 30, 2020

Study Registration Dates

First Submitted

November 23, 2018

First Submitted That Met QC Criteria

November 23, 2018

First Posted (Actual)

November 27, 2018

Study Record Updates

Last Update Posted (Actual)

May 27, 2020

Last Update Submitted That Met QC Criteria

May 24, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Embolism

Clinical Trials on MRI

3
Subscribe